ArticleJournal of dermatological science2020
SJS/TEN 2019: From science to translation.
Erratum issuedOpen access · greenAbstract read
In one paragraph
Article in Journal of dermatological science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 33 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 2 pooled it
7.3field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- Analysis of clinical features of oxcarbazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis.Frontiers in medicine · 2023Pooled it
- Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review of PubMed/MEDLINE case reports from 1980 to 2020.Frontiers in medicine · 2022Pooled it
- The immunogenicity and safety of adenoviral-based vaccines.Current opinion in allergy and clinical immunology · 2026Review
- Prospective longitudinal study of psychological sequelae, self-perception of body image, and quality of life in severe cutaneous adverse drug reactions: a case-control study.Frontiers in medicine · 2026Article
- Comparative Impact of NSAIDs Versus Acetaminophen on Mortality in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Retrospective Cohort Study of 2484 Patients From a Nationwide Inpatient Database.The Journal of dermatology · 2026Article
- Toxic Epidermal Necrolysis Induced by First-Line Helicobacter pylori Eradication Therapy: A Case Report.The Korean journal of helicobacter and upper gastrointestinal research · 2025Article
- Identifying New Candidate Predictors of Mortality in Japanese Patients with Severe Drug Eruptions.Drug safety · 2025Article
- Challenges in Diagnosing and Treatment of Pediatric Necrotic Skin Conditions: A Retrospective Study.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- Improving Recruitment Through Social Media and Web-Based Advertising to Evaluate the Genetic Risk and Long-Term Complications in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Community-Based Survey.Journal of medical Internet research · 2025Article
- Liver Injury in Immune Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Five New Classification Types.Journal of clinical and translational hepatology · 2025Review
- Emerging causes of anticancer therapies-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: evidence from disproportionality analysis of the FDA adverse event reporting system.Frontiers in immunology · 2025Article
- Age-stratified pharmacovigilance of azithromycin: a multimethod signal detection analysis in the FAERS database.Journal of pharmaceutical policy and practice · 2025Article
- Understanding the Gap Between Acute Complications and Long-Term Sequelae in Patients with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Bandung, West Java, Indonesia: Experience from Two Institutions.Clinical, cosmetic and investigational dermatology · 2025Article
- Article
- Stevens-Johnson Syndrome/Toxic epidermal necrolysis complicated with fulminant type 1 diabetes mellitus: a case report and literature review.BMC endocrine disorders · 2024Review
- The Australasian Registry for Severe Cutaneous Adverse Reactions (AUS-SCAR) - Providing a roadmap for closing the diagnostic, patient, and healthcare gaps for a group of rare drug eruptions.The World Allergy Organization journal · 2024Article
- Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Analysis of the Russian Database of Spontaneous Reports.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Phenytoin-Associated Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Overlap in Focus: A Case Report.Cureus · 2023Article
- Correlations between histopathologic findings, serum biomarker levels, and clinical outcomes in Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN).Scientific reports · 2023Article
- Cost-effectiveness ofPharmacogenomics · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
70 authors at 20 institutions in 15 countries.
Wan-Chun ChangDivision of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada; British Columbia Children's Hospital Research Institute, Vancouver, BC, Canada.
Riichiro AbeNiigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Paul AndersonStevens-Johnson Syndrome Foundation, Westminster, CO, USA.
Wanpen AndersonStevens-Johnson Syndrome Foundation, Westminster, CO, USA.
Michael R Ardern-JonesFaculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, UK.
Thomas M BeachkofskyWilford Hall Ambulatory Surgical Center, Lackland Air Force Base, TX, USA.
Teresa BellónDrug Hypersensitivity Group, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.
Agnieszka K BialaDivision of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada; British Columbia Children's Hospital Research Institute, Vancouver, BC, Canada.
Charles BouchardLoyola University Medical Center, Chicago, IL, USA.
Gianpiero L CavalleriSchool of Pharmacy and Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland; FutureNeuro SFI Research Centre, Royal College of Surgeons in Ireland, Dublin, Ireland.
Nicole ChapmanSJS Awareness Oregon, Klamath Falls, OR, USA.
James ChodoshMassachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.
Hyon K ChoiDivision of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, USA.
Ricardo R CibottiNational Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, USA.
Sherrie J DivitoDepartment of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Karen DewarGenome Canada, Ottawa, ON, Canada.
Ulrike DehaeckDepartment of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada.
Mahyar EtminanDepartment of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, BC, Canada.
Diane ForbesCanadian Institutes of Health Research, Ottawa, ON, Canada.
Esther FuchsDepartment of Obstetrics and Gynecology, University of Washington, Seattle, WA, USA.
Jennifer L GoldmanChildren's Mercy Hospital Kansas City, Kansas City, MO, USA.
James H HolmesWake Forest University School of Medicine, WFBMC Burn Center, Winston-Salem, NC, USA.
Elyse A HopeGenome British Columbia, Vancouver, BC, Canada.
Shuen-Iu HungCancer Vaccine and Immune Cell Therapy Core Laboratory, Chang Gung Immunology Consortium, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan; Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan.
Chia-Ling HsiehEden Social Welfare Foundation, Taipei, Taiwan.
Alfonso IovienoDepartment of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver General Hospital Eye Care Center, Vancouver, BC, Canada.
Julienne JagdeoGenome British Columbia, Vancouver, BC, Canada.
Mee Kum KimDepartment of Ophthalmology, Seoul National University College of Medicine, Seoul, South Korea.
David M KoelleDepartment of Medicine, University of Washington, Seattle, WA, USA.
Mario E LacoutureMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Sophie Le PallecAssociation des malades des syndromes de Lyell et de Stevens-Johnson (Amalyste), Paris, France.
Rannakoe J LehloenyaDivision of Dermatology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Robyn LimHealth Products and Food Branch, Health Canada, Ottawa, ON, Canada.
Angie LoweSJS/TEN International Awareness (STIA), Lucky Lake, SK, Canada.
Jean McCawleyStevens-Johnson Syndrome Foundation, Westminster, CO, USA.
Julie McCawleyStevens-Johnson Syndrome Foundation, Westminster, CO, USA.
Robert G MichelettiDepartment of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Maja MockenhauptDokumentationszentrum schwerer Hautreaktionen (dZh), Department of Dermatology, Medical Center and Medical Faculty, University of Freiburg, Freiburg, Germany.
Katie NiemeyerSJ Syndrome of Texas, Austin, TX, USA.
Michael A NorcrossLaboratory of Immunology, Division of Biotechnology Review and Research III (DBRR III), Office of Biotechnology Products (OBP), Office of Pharmaceutical Quality (OPQ), Center for Drug Evaluation and Research (CDER), FDA, Silver Spring, MD, USA.
Douglas ObohStevens-Johnson Syndrome Foundation, Westminster, CO, USA.
Cristina OlteanuDivision of Dermatology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Helena B PasiekaDepartment of Dermatology, MedStar Washington Hospital Center, Washington, DC, USA.
Jonathan PeterDivision of Allergy and Clinical Immunology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Munir PirmohamedDepartment of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.
Michael RiederDepartment of Paediatrics, Children's Hospital/London Health Sciences Centre, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.
Hajirah N SaeedMassachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.
Neil H ShearSunnybrook Health Sciences Centre, University of Toronto, ON, Canada.
Christine ShiehDepartment of Ophthalmology, Vanderbilt Eye Institute, Nashville, TN, USA.
Sabine StrausDutch Medicines Evaluation Board, Pharmacovigilance Risk Assessment Committee, European Medicines Agency, Utrecht, the Netherlands.
Chonlaphat SukasemRamathibodi Hospital, Mahidol University, Bangkok, Thailand.
Cynthia SungHealth Products Regulation Group, Health Sciences Authority Singapore, Duke-NUS Medical School, Singapore.
Jason A TrubianoDepartment of Infectious Diseases, Austin Health, Heidelberg, Germany; Department of Medicine, University of Melbourne, Victoria, Australia.
Sheng-Ying TsouEden Social Welfare Foundation, Taipei, Taiwan.
Mayumi UetaDepartment of Frontier Medical Science and Technology for Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Simona VolpiNational Human Genome Research Institute, NIH, Bethesda, MD, USA.
Chen WanGenome British Columbia, Vancouver, BC, Canada.
Hongsheng WangInstitute of Dermatology, Chinese Academy of Medical Sciences, National Center for STD and Leprosy Control, China CDC, Nanjing, China.
Zhao-Qing WangEden Social Welfare Foundation, Taipei, Taiwan.
Jessica WeintraubDivision of Pharmacovigilance I, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, USA.
Cindy WhaleSJS Canada, Brantford, ON, Canada.
Lisa M WheatleyNational Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA.
Sonia Whyte-CroasdaileSJS Canada, Brantford, ON, Canada.
Kristina B WilliamsDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
Galen WrightDivision of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada; British Columbia Children's Hospital Research Institute, Vancouver, BC, Canada.
Sonia N YeungDepartment of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver General Hospital Eye Care Center, Vancouver, BC, Canada.
Li ZhouDivision of General Internal Medicine and Primary Care, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Wen-Hung ChungDepartment of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taipei, Keelung, Taoyuan, Taiwan; Cancer Vaccine and Immune Cell Therapy Core Laboratory, Chang Gung Immunology Consortium, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan; College of Medicine, Chang Gung University, Taoyuan, Taiwan; Department of Dermatology, Xiamen Chang Gung Hospital, Xiamen, China; Whole-Genome Research Core Laboratory of Human Diseases, Chang Gung Memorial Hospital, Keelung, Taiwan. Electronic address: chung1@cgmh.org.tw.
Elizabeth J PhillipsDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA; Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Australia; Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address: elizabeth.j.phillips@vumc.org.
Bruce C CarletonDivision of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada; British Columbia Children's Hospital Research Institute, Vancouver, BC, Canada. Electronic address: bcarleton@popi.ubc.ca.
Rome Foundation · USUniversity of British Columbia · CAGenome British Columbia · CACenter for Drug Evaluation and Research · USHarvard University · USUniversity of Cape Town · ZAUniversity of Washington · USVancouver General Hospital · CAVanderbilt University Medical Center · USBC Children's Hospital · CABrigham and Women's Hospital · USCanadian Institutes of Health Research · CAChildren's Mercy Hospital · USChinese Academy of Medical Sciences Dermatology Hospital · CNGenome Canada · CAHealth Canada · CAHealth Sciences Authority · SGHealth Sciences Centre · CAHospital La Paz Institute for Health Research · ESKyoto Prefectural University of Medicine · JP
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MInvestigating a novel cell population in delayed-onset drug hypersensitivity reactionsDP5OD023091 · OD · BRIGHAM AND WOMEN'S HOSPITAL · PI DIVITO, SHERRIE JILL · 2016 to 2020
$2.1MIMmune-mediated Adverse drug Reactions In African HIV endemic setting (IMARI-SA study)K43TW011178 · FIC · UNIVERSITY OF CAPE TOWN LUNG INSTITUTE · PI PETER, JONATHAN · 2018 to 2022
$648kStevens-Johnson Syndrome/Toxic Epidermal Necrolysis 2019: From Science to TranslationR13AR074889 · NIAMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2019 to 2019
$39kFIC NIH HHS K43 TW011178Medical Research Council MR/L006758/1NCI NIH HHS P30 CA008748NIAMS NIH HHS R13 AR074889NIH HHS DP5 OD023091
Abstract
Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are potentially life-threatening, immune-mediated adverse reactions characterized by widespread erythema, epidermal necrosis, and detachment of skin and mucosa. Efforts to grow and develop functional international collaborations and a multidisciplinary interactive network focusing on SJS/TEN as an uncommon but high burden disease will be necessary to improve efforts in prevention, early diagnosis and improved acute and long-term management. SJS/TEN 2019: From Science to Translation was a 1.5-day scientific program held April 26-27, 2019, in Vancouver, Canada. The meeting successfully engaged clinicians, researchers, and patients and conducted many productive discussions on research and patient care needs.
Indexed as
Congresses as TopicGlobal Burden of DiseaseGlobal HealthHealth Services Needs and DemandHumansInternational CooperationPatient Care TeamPharmacogeneticsRegistriesStevens-Johnson SyndromeTranslational Research, BiomedicalHuman leukocyte antigen (HLA)PharmacogenomicsPharmacovigilanceSevere cutaneous adverse reaction (SCAR)Stevens-Johnson syndrome (SJS)Toxic epidermal necrolysis (TEN)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.